Abstract:Background. The prognosis of patients with multiple myeloma (MM) is significantly different depending on the biological characteristics of the tumor substrate, the microenvironment of the bone marrow, as well as factors associated with the patient’s body. Therefore, the search for new reliable and easily identifiable prognostic markers is relevant for the effective management of patients with this disease. The objective of the study was to assess the prognostic value of the study of serum free light chains (FLC) of immunoglobulins κ and λ and their ratio κ / λ FLC in the blood serum of patients with newly diagnosed MM in real clinical practice. Materials and methods. 369 patients with first diagnosed MM (134 men and 235 women) were examined who were hospitalized in the hematology department of the City Clinical Hospital No. 2 Novosibirsk in the period since January 2012 to December 2017. The median age of the patients was 67 (32–82) years. All patients received induction courses of chemotherapy based on bortezomib. The control group consisted of 56 conditionally healthy individuals: 34 women (60.7 %) and 22 (39.3 %) men with a median age of 62 (40–68) years. The concentration of FLC-κ and FLC-λ (mg / L) in blood serum was determined by immunoturbidimetric method on a Hitachi 911 automated biochemical analyzer using the Freelite Human Lambda and Freelite Human Kappa reagent kits (Binding Site, Great Britain). Results. It was found that in patients with MM, the concentration of serum FLC-κ or FLC-λ was statistically significantly higher compared to the control group and varied depending on the type of MM (p <0.001). The diagnostic sensitivity of the quantitative determination of FLC and their ratio for MM was 98.64 %, compared with 94.04 % in a standard immunochemical study. The values of the ratio κ / λ FLC 65, as well as the concentration of FLC-κ and FLC-λ are higher than the median obtained in the whole group (FLC-κ ≥702 mg / L and FLC-λ ≥493.2 mg / L), correlate with known factors of poor prognosis for MM (with a high concentration of β2‐microglobulin (>3.5 mg / L) (r = 0.461; p 60 % (r = 0.420; p 177 μmol / L) (r = 0.380; p = 0.002), and also with high lactate dehydrogenase activity (>450 U / L) (r = 0.520; p <0.001) and is associated with poor outcomes. The median overall survival in the group of patients with κ / λ FLC 65 was 49 months compared to 76 months in the group with κ / λ FLC 0.04–65 (log-rank p = 0.012). Conclusion. The determination of free FLC in the blood serum of patients with MM can be used to assess the prognosis of their survival. The value of the κ / λ FLC ratio 65 allows us to divide patients with MM into risk groups with significantly different outcomes and can be used to identify patients at high risk who need more aggressive therapy and more detailed monitoring of the response.

The role of immunoglobulin heavy/light chain detection in the prognosis of IgA multiple myeloma

[Effect of Immunoglobulin Heavy/light Chain Detection on the Minimal Residual Disease Monitoring in IgG Multiple Myeloma Patients].

The response assessment value of serum free light chain in the chemotherapy for IgG multiple myeloma

[The Significance of Serum IgD Quantitation for Evaluation of Clinical Efficacy in IgD Multiple Myeloma].

The Significance of Detecting the Clonal Rearrangements of Immunoglobulin Heavy ChainGene in Peripheral Blood Cells of Patients with Multiple Myeloma

The Application of Quantitative Detection of Serum Immunoglobulin and Light Chain in Multiple Myeloma Condition Mo-nitoring

Clinical characteristics and prognosis analysis of 130 cases with IgD multiple myeloma

The clinical application of serum κ/λ light chain ratio and protein electrophoresis in the diagnosis of multiple myeloma

The Landscape of Cytogenetic Aberrations in Light-Chain Amyloidosis with or Without Coexistent Multiple Myeloma.

The importance of serum immunoglobulin free light chain assessment for predicting outcome in patients with newly diagnosed multiple myeloma in real clinical practice

Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma

The clinical value of serum free light chain measurement in multiple myeloma

[Evaluation and comparison of prognostic value of serum free light chain ratio/difference in patients with newly diagnosed multiple myeloma].

Polyclonal Serum IgM Level Identifies a Subgroup of Multiple Myeloma Patients with Low-Risk Clinicobiological Features and Superior Survival

[Measurement of Serum Free Light Chains and Its Clinical Significance in 20 Newly Diagnosed Patients of Multiple Myeloma].

Minimal Residual Disease Detection by Next-Generation Sequencing of Different Immunoglobulin Gene Rearrangements in Pediatric B-ALL

Analysis of Serum IgG1 to Predict Progression and Therapeutic Effect in Patients with Multiple Myeloma

Application of Detection of IgH Gene Rearrangements in the Patients with Multiple Myeloma

Further Stratification Of Patients With Multiple Myeloma By International Staging System In Combination With Ratio Of Serum Free Kappa To Lambda Light Chains

Clinical Significance of Serum Free Light Chain Test in the First Onset of Multiple Myeloma

Value of Serum Free Light Chain in Differential Diagnosis of Hypergammaglobulinemia